# Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab

> The FDA approved Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab), sponsored by Merck & Co., Inc. (MRK), on September 19, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) FDA approved?

Yes. The FDA approved Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab), sponsored by Merck & Co., Inc. (MRK), on September 19, 2025. FDA novel drug approvals: "Keytruda Qlex | pembrolizumab and berahyaluronidase alfa-pmph | 9/19/2025 | To treat adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab" [Calendar and source filings](https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) |
| Codes |  |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications |  |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### September 19, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Keytruda Qlex | pembrolizumab and berahyaluronidase alfa-pmph | 9/19/2025 | To treat adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
- openFDA Drugs@FDA: "BLA761467 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20250919, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22
- openFDA Drugs@FDA: "BLA761467 ORIG-2 (Efficacy): submission_status AP, submission_status_date 20250919, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22

### November 21, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761467 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20251121, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22

### February 10, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761467 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20260210, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22

### April 24, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761467 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20260424, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22

### June 12, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761467 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20260612, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22

### June 24, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761467 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20260624, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22

### July 10, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761467 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20260710, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22

### October 16, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761467 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20261016, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab

```bibtex
@misc{secapidev_pdufa_berahyaluronidase_alfa_pmph_pembrolizumab_20261116,
  title        = {Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_berahyaluronidase_alfa_pmph_pembrolizumab_20261116","title":"Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
